fbpx

List – 55 Drug Patents that are Expiring in 2026

Which drug patents are expiring in 2023? how about 2024? and 2025?

There are about a dozen websites on the internet answering this very question. We can definitely do better than that. How about the list of drugs that are going off-patent in 2026? Much better. Don’t you like to stay a step ahead of your competitors! We get you.

With the huge growth in the generic drug market, there is no doubt that generic companies (hey there!) are searching for drugs with a soon-to-be-expired label. To make their (your) work easy, we collected not just the drug names, but also included other information like yearly sales, treatment, ingredients, and the disease they cure which could help them (you) easily choose the drug most profitable to develop a generic version 4 years in advance. 

So, without any delay, here is the list of drug patents expiring in 2026. Thank us later!

The article has a list of drug patents in 2026. If you want to backtrack a little and get the drug patents expiration list from 2021 to 2025, Download the PDF by filling out the form below.


Drug Patents Expiring in 2026

Avycaz
Ceftazidime / Avibactam

More information about this Drug

Patents Expiration Date
US7112592 January 7, 2026
US8471025 August 12, 2031
US9284314 June 15, 2032
US9695122 June 15, 2032
US8969566 June 15, 2032

Dosage:  Intravenous infusion
Company: Allergan
Ingredients: AVIBACTAM SODIUM; CEFTAZIDIME
Treatment: Intra-abdominal Infections, Urinary Tract Infections, and Pneumonia

Tavalisse
Fostamatinib

More information about this Drug

Patents Expiration Date
US8211889 January 19, 2026
US7538108 March 28, 2026
US7989448 June 12, 2026
US8163902 June 17, 2026
US7449458 September 4, 2026

Dosage:  Oral
Company: Rigel Pharmaceuticals
Ingredients: FOSTAMATINIB DISODIUM
Treatment: Chronic Immune Thrombocytopenia

Bridion
Sugammadex

More information about this Drug

Patents Expiration Date
USRE44733 January 27, 2026

Dosage: Intravenous
Company: Merck & Co., Inc
Ingredients: SUGAMMADEX SODIUM
Treatment: Reversal of Neuromuscular Blockade Induced by Rocuronium

Briviact
Brivaracetam

More information about this Drug

Patents Expiration Date
US6911461 February 21, 2026

Dosage: Oral, Intravenous
Company: UCB Group
Ingredients: BRIVARACETAM
Treatment: Partial-onset Seizures in People 1 month of age and older

Procoralan
Ivabradine

More information about this Drug

Patents Expiration Date
US7361650 February 22, 2026
US7361649 February 22, 2026
US7879842 February 22, 2026
US7867996 December 12, 2026

Dosage: Oral
Company: Servier
Ingredients: IVABRADINE
Treatment: Symptomatic Management of Stable Heart-related Chest Pain and Heart Failure

Pradaxa
Dabigatran

More information about this Drug

Patents Expiration Date
US7932273 March 7, 2026

Dosage: Oral
Company: Boehringer Ingelheim
Ingredients: DABIGATRAN ETEXILATE MESYLATE
Treatment: Blood clots, Stroke

Ozempic
Semaglutide

More information about this Drug

Patents Expiration Date
US8536122 March 20, 2026
US8129343 December 5, 2031

Dosage: Oral, Subcutaneous
Company: Novo Nordisk
Ingredients: SEMAGLUTIDE
Treatment: Type 2 Diabetes

Byetta
Exenatide

More information about this Drug

Patents Expiration Date
US6515117 April 4, 2026

Dosage: Subcutaneous
Company: AstraZeneca
Ingredients: EXENATIDE SYNTHETIC
Treatment: Type 2 Diabetes

Rexulti
Brexpiprazole

More information about this Drug

Patents Expiration Date
US7888362 April 12, 2026
USRE48059 December 23, 2028

Dosage: Oral
Company: Otsuka America Pharmaceutical
Ingredients: BREXPIPRAZOLE
Treatment: Schizophrenia, Major Depressive Disorder

Aveed
Nebido

More information about this Drug

Patents Expiration Date
US11179402 April 14, 2026
US10617696 April 12, 2030

Dosage: Oral, Intramuscular injection
Company: Endo Pharmaceuticals
Ingredients: TESTOSTERONE UNDECANOATE
Treatment: Low Testosterone Levels in Men

Aptiom
Eslicarbazepine acetate

More information about this Drug

Patents Expiration Date
US9206135 April 21, 2026

Dosage: Oral
Company: Sumitomo Pharma Co
Ingredients: ESLICARBAZEPINE ACETATE
Treatment: Partial-onset Seizures Epilepsy

Vocabria
Cabotegravir

More information about this Drug

Patents Expiration Date
US8410103 April 28, 2026
US10927129 April 28, 2026

Dosage: Oral, Intramuscular Injection
Company: ViiV Healthcare
Ingredients: CABOTEGRAVIR
Treatment: HIV/AIDS

Jevtana
Cabazitaxel

More information about this Drug

Patents Expiration Date
US7241907 June 10, 2026

Dosage: Intravenous
Company: Sanofi-aventis
Ingredients: CABAZITAXEL
Treatment: Metastatic Castration-resistant Prostate Cancer

Voltaren
Diclofenac

More information about this Drug

Patents Expiration Date
US8097651 June 16, 2026
US7759394 June 16, 2026

Dosage: Oral, Rectal, Intramuscular, Intravenous, Topical
Company: GSK
Ingredients: DICLOFENAC POTASSIUM
Treatment: Inflammatory Diseases such as Gout

Trintellix
Vortioxetine

More information about this Drug

Patents Expiration Date
US7144884 June 17, 2026
US8722684 June 30, 2031

Dosage: Oral
Company: Takeda Pharmaceuticals
Ingredients: VORTIOXETINE HYDROBROMIDE
Treatment: Major Depressive Disorder

Zelboraf
Vemurafenib

More information about this Drug

Patents Expiration Date
US8143271 June 21, 2026
US7504509 October 22, 2026
US7863288 June 20, 2029
US8741920 July 27, 2030

Dosage: Oral
Company: Genentech
Ingredients: VEMURAFENIB
Treatment: Late-stage Melanoma

Rhopressa
Netarsudil

More information about this Drug

Patents Expiration Date
US8450344 July 11, 2026
US9096569 July 11, 2026
US10174017 January 27, 2030
US10654844 January 27, 2030
US8394826 November 10, 2030
US9931336 March 14, 2034
US10588901 March 14, 2034
US9415043 March 14, 2034

Dosage: Eye drops, Topical
Company: Aerie Pharmaceuticals
Ingredients: NETARSUDIL MESYLATE
Treatment: Glaucoma

Gilotrif
Afatinib

More information about this Drug

Patents Expiration Date
USRE43431 July 13, 2026
US8426586 April 10, 2030

Dosage: Oral
Company: Boehringer Ingelheim
Ingredients: AFATINIB DIMALEATE
Treatment: Non-small Cell Lung Carcinoma

Beleodaq
Belinostat

More information about this Drug

Patents Expiration Date
US6888027 August 10, 2026

Dosage: Intravenous
Company: Acrotech Biopharma LLC
Ingredients: BELINOSTAT
Treatment: Hematological Malignancies and Solid Tumors

Cometriq
Cabozantinib

More information about this Drug

Patents Expiration Date
US7579473 August 14, 2026
US11091439 January 15, 2030
US8877776 October 8, 2030

Dosage: Oral
Company: Exelixis, Inc
Ingredients: CABOZANTINIB S-MALATE
Treatment: Medullary Thyroid Cancer, Renal Cell Carcinoma, and Hepatocellular Carcinoma

Isturisa
Osilodrostat

More information about this Drug

Patents Expiration Date
US8835646 August 23, 2026
US8314097 March 27, 2029
US9434754 January 13, 2031

Dosage: Oral
Company: Recordati Rare Diseases Inc
Ingredients: OSILODROSTAT PHOSPHATE
Treatment: Cushing’s Disease

Samsca
Tolvaptan

More information about this Drug

Patents Expiration Date
US8501730 September 1, 2026

Dosage: Oral
Company: Otsuka America Pharmaceutical
Ingredients: TOLVAPTAN
Treatment: Hyponatremia

Sprycel
Dasatinib

More information about this Drug

Patents Expiration Date
US7491725 September 28, 2026

Dosage: Oral
Company: Bristol-Myers Squibb
Ingredients: DASATINIB
Treatment: Chronic Myelogenous Leukemia (CML) and Acute Lymphoblastic Leukemia

Aklief
Trifarotene

More information about this Drug

Patents Expiration Date
US7807708 October 1, 2026

Dosage: Topical
Company: Galderma Laboratories
Ingredients: TRIFAROTENE
Treatment: Acne Vulgaris

Symproic
Naldemedine

More information about this Drug

Patents Expiration Date
USRE46375 October 5, 2026
USRE46365 January 11, 2028
US9108975 November 11, 2031
US10952968 May 13, 2033

Dosage: Oral
Company: Shionogi & Co
Ingredients: NALDEMEDINE TOSYLATE
Treatment: Opioid-induced Constipation

Saphris
Asenapine

More information about this Drug

Patents Expiration Date
US7741358 October 6, 2026
US8022228 October 6, 2026

Dosage: Sublingual
Company: Merck Sharp & Dohme
Ingredients: ASENAPINE MALEATE
Treatment: Schizophrenia

Uptravi
Selexipag

More information about this Drug

Patents Expiration Date
US7205302 October 31, 2026
US8791122 August 1, 2030

Dosage: Oral, intravenous
Company: Actelion Pharmaceuticals
Ingredients: SELEXIPAG
Treatment: Pulmonary Arterial Hypertension

Bevyxxa
Betrixaban

More information about this Drug

Patents Expiration Date
US7598276 November 8, 2026

Dosage: Oral
Company: Portola Pharmaceuticals, Inc
Ingredients: BETRIXABAN
Treatment: Venous Thrombosis

Orkambi
Lumacaftor / Ivacaftor

More information about this Drug

Patents Expiration Date
US9216969 November 8, 2026
US10597384 December 4, 2028
US8507534 September 20, 2030

Dosage: Oral
Company: Vertex Pharmaceuticals
Ingredients: IVACAFTOR; LUMACAFTOR
Treatment: Cystic Fibrosis

Eliquis
Apixaban

More information about this Drug

Patents Expiration Date
US6967208 November 21, 2026

Dosage: Oral
Company: Bristol-Myers Squibb
Ingredients: APIXABAN
Treatment: Blood Clots

Calquence
Acalabrutinib

More information about this Drug

Patents Expiration Date
US7459554 November 24, 2026
US9290504 July 11, 2032
US9796721 July 1, 2036

Dosage: Oral
Company: AstraZeneca
Ingredients: ACALABRUTINIB
Treatment: Non-Hodgkin Lymphoma, Mantle Cell Lymphoma

Sirturo
Bedaquiline

More information about this Drug

Patents Expiration Date
US7498343 December 1, 2026
US8546428 March 19, 2029

Dosage: Oral
Company: Janssen Therapeutics
Ingredients: BEDAQUILINE FUMARATE
Treatment: Multi-drug-resistant Tuberculosis

Adempas
Riociguat

More information about this Drug

Patents Expiration Date
US7173037 December 4, 2026
US10662188 February 18, 2034
US11203593 February 18, 2034

Dosage: Oral
Company: Bayer
Ingredients: RIOCIGUAT
Treatment: Pulmonary Hypertension

Moxatag
Amoxicillin

More information about this Drug

Patents Expiration Date
US8778924 December 8, 2026

Dosage: Oral, intravenous
Company: Pragma Pharmaceuticals
Ingredients: AMOXICILLIN
Treatment: Bacterial Infections

Inrebic
Fedratinib

More information about this Drug

Patents Expiration Date
US7528143 December 16, 2026
US7825246 December 16, 2026

Dosage: Oral
Company: Impact Biomedicines
Ingredients: FEDRATINIB HYDROCHLORIDE
Treatment: Myeloproliferative

Imbruvica
Ibrutinib

More information about this Drug

Patents Expiration Date
US8697711 December 28, 2026
US9181257 December 28, 2026
US8957079 December 28, 2026
US8735403 December 28, 2026
US7514444 December 28, 2026
US8008309 November 13, 2027
US10125140 June 3, 2033
US9725455 June 3, 2033
US10106548 June 3, 2033
US9296753 October 30, 2033

Dosage: Oral
Company: Janssen Biotech
Ingredients: IBRUTINIB
Treatment: Chronic Lymphocytic Leukemia

Kalydeco
Ivacaftor

More information about this Drug

Patents Expiration Date
US8754224 December 28, 2026
US7495103 May 20, 2027

Dosage: Oral
Company: Vertex Pharmaceuticals
Ingredients: IVACAFTOR
Treatment: Cystic Fibrosis

Conclusion

Don’t you like to be on top of things? Well, so do we. And so, we got our pharma team working round the clock finding drug patents that are expiring 8 years from now. Yes, we like to be avant-garde. So if you want to stay ahead too subscribe to us and get the latest updates on drug patents that are expiring in the coming years!

Authored By: Divya Goyal, Team Lead, Life Science Team.

Leave a Comment